Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
155.7 ^USD	-2.12%		-5.06%	+25.49%

Apr. 22	Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung	CI
Apr. 16	Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating	MT

Krystal Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020

March 01, 2021 at 08:16 am EST

Krystal Biotech, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced operating loss was USD 32.999 million compared to USD 22.081 million a year ago. Net loss was USD 32.167 million compared to USD 19.088 million a year ago. Basic loss per share from continuing operations was USD 1.71 compared to USD 1.2 a year ago.

Latest news about Krystal Biotech, Inc.

Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung	Apr. 22	CI
Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating	Apr. 16	MT
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing	Mar. 12	MT
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing	Mar. 12	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 26	MT
Sector Update: Health Care Stocks Weaker Monday Afternoon	Feb. 26	MT
Top Midday Gainers	Feb. 26	MT
Krystal Biotech Shares Jump After Surprise Q4 Profit	Feb. 26	MT
Krystal Biotech Swings to Q4 Profit as Company Generates Revenue; Shares Climb Pre-Bell	Feb. 26	MT
Transcript : Krystal Biotech, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
Krystal Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
Earnings Flash (KRYS) KRYSTAL BIOTECH Posts Q4 EPS $0.30, vs. Street Est of $-0.25	Feb. 26	MT
Krystal Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
North American Morning Briefing : Traders Await Inflation Data This Week	Feb. 26	DJ
MORNING BID AMERICAS-Booming stocks step back as PCE hoves into view	Feb. 26	RE
Krystal Biotech Says FDA Grants Fast Track Designation to Inhaled KB707 for Lung Tumors Treatment	Feb. 13	MT
Krystal Biotech Secures J-code for Vyjuvek	Jan. 04	MT
Krystal Biotech Receives Permanent J-Code for VYJUVEK®	Jan. 04	CI
Krystal Biotech Says Japan Grants Orphan Drug Designation to Skin Disease Treatment; Shares Rise Pre-Bell	Dec. 19	MT
Krystal Biotech Insider Sold Shares Worth $5,283,291, According to a Recent SEC Filing	Dec. 12	MT
Krystal Biotech Insider Sold Shares Worth $5,283,291, According to a Recent SEC Filing	Dec. 12	MT
Krystal Biotech Says European Regulator Validates Marketing Authorization Application for Skin Disease Treatment	Nov. 27	MT
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for Vyjuvek for the Treatment of Dystrophic Epidermolysis Bullosa	Nov. 27	CI
Sector Update: Health Care Stocks Advance Premarket Monday	Nov. 06	MT
Transcript : Krystal Biotech, Inc., Q3 2023 Earnings Call, Nov 06, 2023	Nov. 06

Chart Krystal Biotech, Inc.

Duration

Period

More charts

Company Profile

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patientâs skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Krystal Biotech, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

155.7 USD

Average target price

188.5 USD

Spread / Average Target

+21.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KRYSTAL BIOTECH, INC.	+25.49%	4.54B
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs